Managing Melanoma Treatment Toxicities: Strategies for Enhanced Patient Care - Module 2

Claim your CME and NCPD here: https://bit.ly/4cVoUe4

Melanoma treatments, including immunotherapy and targeted therapies, have revolutionized care but can lead to significant immune-related toxicities. In this module, Dr. Michael A. Davies from MD Anderson Cancer Center discusses evidence-based strategies for managing adverse events, employing interdisciplinary supportive care, and educating patients to optimize outcomes. Stay updated on best practices to enhance melanoma patient care.

STATEMENT OF NEED

Melanoma is a complex disease which has seen remarkable progress in recent years due to the introduction of immunotherapy and targeted therapies. While emerging treatments have prolonged survival and improved outcomes, they can be associated with significant toxicities that impact organ systems throughout the body (Brahmer et al, 2021; Boutros et al, 2024). In order to maximize the efficacy of novel therapies, it is vital for members of the care team to remain up to date on the management of immune-related adverse events, employ interdisciplinary supportive care strategies, and provide clear and effective education to their patients. In Module 2 of this activity, Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, will explore strategies for enhancing patient care and keeping pace with advancements in melanoma.

TARGET AUDIENCE

Oncologists, dermatologists, advanced practice providers, nurses, and other healthcare professionals (HCPs) involved in the treatment of patients with melanoma.

LEARNING OBJECTIVE

Upon completion of this activity, participants should be able to

Implement evidence-based protocols in managing immune-mediated adverse events and best practices in supportive care to enhance patient outcomes

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Michael A. Davies, MD, PhD, discloses that he has served on an advisory board or panel for ABM, Apexigen, Bristol Myers Squibb, Eisai, Iovance, Novartis, Nurix, Pfizer, Replimune, and Roche; and that he has received grants/research support from ABM, Lead Pharma, and Pfizer.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must watch the video and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD activities, include access to system requirements:

The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.
UNAPPROVED USE DISCLOSURE

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC.

#Melanoma #CancerTreatment #Immunotherapy #TargetedTherapies #OncologyEducation #PersonalizedMedicine #SkinCancer #MedicalEducation #HealthcareProfessionals